Cardiologist Dinner Takes: How will CARDIO-TTRansform change the ATTR treatment paradigm?

Research evidence excerpt

Cardiologist Dinner Takes: How will CARDIO-TTRansform change the ATTR treatment paradigm?

Equity Research

27 May 2026

Cardiologist Dinner Takes

How will CARDIO-TTRansform

change the ATTR treatment

BBIO OVERWEIGHTparadigm?

U.S. Small & Mid Cap POSITIVE

We hosted a doc for an investor dinner in NY. We think Biotechnology Price Target USD 157.00

CARDIO-TTRansform could be beneficial for silencer class, Price (26-May-26) USD 67.73

getting combination potentially in guidelines (even w/just Potential Upside/Downside +131.8% Source: Bloomberg, Barclays Research

trends). Physician prefers Amvuttra due to Part B economics

ALNY OVERWEIGHT(340B center).

U.S. Small & Mid Cap POSITIVE Biotechnology

Price Target USD 527.00We think CARDIO-TTRansform is likely to hit, but with a lower effect size than HELIOS-B &

Price (26-May-26) USD 295.50ATTRibute given the patient demographics. KOL views IONS' CARDIO-TTRansform as a read to

Potential Upside/Downside +78.3%the silencer class (vs. specific to eplontersen), though in his prescribing he prefers Amvuttra

Source: Bloomberg, Barclays Research

given the economics in his center preferring part B.

We hosted a cardiologist and KOL practicing at a large urban academic medical center who is IONS OVERWEIGHT

involved in the ATTR treatment guidelines, to discuss the evolving treatment landscape in ATTR- U.S. Small & Mid Cap POSITIVE Biotechnology

CM (ALNY, BBIO, IONS in our coverage); we also touched on PAH/PH-ILD (INSM, GOSS in our Price Target USD 115.00

coverage). Key takes from our discussion: Price (26-May-26) USD 76.07

Potential Upside/Downside +51.2%

•• We think the KOL sounded positive on uptake of ALNY's Amvuttra, particularly at academic Source: Bloomberg, Barclays Research

and 340B centers due to favorable buy-and-bill economics.